共 5 条
[1]
Hideshima T(2001)The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells Cancer Res 61 3071-3076
[2]
Orlowski RZ(2002)Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies J Clin Oncol 20 4420-4427
[3]
Richardson PG(2003)A phase 2 study of bortezomib in relapsed, refractory myeloma N Engl J Med 348 2609-2617
[4]
Jagannath S(2005)Bortezomib appears to overcome poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials [abstract #6501] J Clin Oncol 24 560s-3065
[5]
Orlowski RZ(2005)Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies Blood 105 3058-undefined